GlassScriptPhysician profile
Michelle Craver
NPI 1336893999
$4,458.28
in general payments reported to CMS, 2019-2025
23 companies · $703 in 2025
The $703 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,170 · 2023: $1,533 · 2024: $1,052 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $708.13 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $553.42 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $505.10 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $364.77 | 2022-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $346.31 | 2022-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.73 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $271.92 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $256.31 | 2022-2024 | Farxiga, Andexxa |
| Alnylam Pharmaceuticals INC. | $251.90 | 2024-2025 | Onpattro, Amvuttra |
| Pfizer INC. | $239.71 | 2022-2025 | |
| Amgen INC. | $149.28 | 2022-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $132.09 | 2023-2024 | Inpefa |
| Medtronic, INC. | $113.18 | 2023 | Corevalve Evolut R |
| Abiomed | $52.67 | 2024 | |
| Janssen Pharmaceuticals, INC | $42.61 | 2022-2023 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $36.65 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $21.71 | 2024 | Evkeeza |
| Bridgebio Pharma, INC. | $20.54 | 2025 | Attruby |
| Lantheus Medical Imaging, INC. | $18.45 | 2025 | |
| Scpharmaceuticals INC. | $17.26 | 2023 | |
| Esperion Therapeutics, INC. | $16.12 | 2022 | |
| Saranas, INC. | $15.50 | 2022 | |
| Althera Pharmaceuticals LLC | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Craver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.